Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items: 2023-2025

Historic Non-cash Items for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $2.7 million.

  • Contineum Therapeutics' Non-cash Items rose 29.49% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 29.49%. This contributed to the annual value of $21.5 million for FY2024, which is 44.21% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Non-cash Items stood at $2.7 million, which was up 4.83% from $2.6 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Non-cash Items high stood at $33.0 million for Q2 2024, and its period low was $2.0 million during Q1 2024.
  • In the last 3 years, Contineum Therapeutics' Non-cash Items had a median value of $4.3 million in 2025 and averaged $10.6 million.
  • Within the past 5 years, the most significant YoY rise in Contineum Therapeutics' Non-cash Items was 192.68% (2025), while the steepest drop was 92.06% (2025).
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Non-cash Items stood at $14.9 million in 2023, then soared by 44.21% to $21.5 million in 2024, then increased by 29.49% to $2.7 million in 2025.
  • Its Non-cash Items was $2.7 million in Q3 2025, compared to $2.6 million in Q2 2025 and $5.9 million in Q1 2025.